$CBIS Thu, 22 May 2014 11:00:00 GMT ~ Cannabis Sc
Post# of 21196
Posted On: 06/02/2014 11:07:17 AM
$CBIS Thu, 22 May 2014 11:00:00 GMT ~ Cannabis Science Issues CBN Patent and R&D Progress Guidance for the 2nd Quarter of 2014
[PR Newswire] - COLORADO SPRINGS, Colo., May 22, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders. To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer's disease. Earlier this year the company has raised funds to facilitate Cannabis Science's R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the Company's new product to address neurobehavioral disorders. "Cannabis Science has made solid progress so far this year.
read full: http://finance.yahoo.com/news/cannabis-scienc...00335.html
[PR Newswire] - COLORADO SPRINGS, Colo., May 22, 2014 /PRNewswire/ -- Cannabis Science, Inc. (CBIS), a U.S. Company specializing in cannabis formulation-based drug development issues CBN patent and R&D guidance for the 2nd quarter of 2014 to its shareholders. To support its existing CBN patent, the company has delivered pure CBN compound to two research facilities in Europe where testing will be started to establish activity of CBN alone and in combination with other cannabinoids in anxiety, sleep disorders as well as in variety of neurological conditions including Alzheimer's disease. Earlier this year the company has raised funds to facilitate Cannabis Science's R&D activities that will include production of pharmaceutical grade cannabis-based formulations to be developed for variety of illnesses, to continue moving forward its clinical observational studies and to initiate pre-clinical work on the Company's new product to address neurobehavioral disorders. "Cannabis Science has made solid progress so far this year.
read full: http://finance.yahoo.com/news/cannabis-scienc...00335.html
(0)
(0)Scroll down for more posts ▼